Do symptoms predict COPD in smokers?
暂无分享,去创建一个
[1] M. Decramer,et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.
[2] F. Gómez,et al. Characteristics of patients admitted for the first time for COPD exacerbation. , 2009, Respiratory medicine.
[3] E. Bleecker,et al. Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers , 2009, Respiratory research.
[4] S. Antoniu. UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease , 2009, Expert opinion on pharmacotherapy.
[5] P. Jones,et al. Lung function decline in COPD trials , 2009, European Respiratory Journal.
[6] D. Mannino,et al. COPD prevalence in southeastern Kentucky: the burden of lung disease study. , 2009, Chest.
[7] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[8] C. van Weel,et al. Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care , 2008, European Respiratory Journal.
[9] J Stocks,et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction , 2008, Thorax.
[10] P. Calverley,et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.
[11] D. Jarvis,et al. Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes , 2008, Thorax.
[12] M. Barton,et al. Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.
[13] G. Wesseling,et al. External validation of a COPD diagnostic questionnaire , 2008, European Respiratory Journal.
[14] H. Melbye,et al. What role may symptoms play in the diagnosis of airflow limitation? , 2008, Scandinavian journal of primary health care.
[15] Anastasia E. Raczek,et al. Development and Initial Validation of a Self-Scored COPD Population Screener Questionnaire (COPD-PS) , 2008, COPD.
[16] K. Wood,et al. What Defines Abnormal Lung Function in Older Adults with Chronic Obstructive Pulmonary Disease? , 2008, Drugs & aging.
[17] T. Seemungal,et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.
[18] E. Bleecker,et al. IL13 promoter polymorphism 1112C/T modulates the adverse effect of tobacco smoking on lung function. , 2007, American journal of respiratory and critical care medicine.
[19] Shengming Liu,et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. , 2007, American journal of respiratory and critical care medicine.
[20] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[21] D. S. Kim,et al. Determinants of respiratory symptom development in patients with chronic airflow obstruction. , 2006, Respiratory medicine.
[22] M. Cazzola,et al. The role of combination therapy with corticosteroids and long-acting β2-agonists in the prevention of exacerbations in COPD , 2006, International journal of chronic obstructive pulmonary disease.
[23] William M Vollmer,et al. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? , 2006, Thorax.
[24] D. Mannino,et al. Global burden of COPD: systematic review and meta-analysis , 2006, European Respiratory Journal.
[25] K. Wood,et al. FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. , 2006, Chest.
[26] A. Gulsvik,et al. Post-bronchodilator spirometry reference values in adults and implications for disease management. , 2006, American journal of respiratory and critical care medicine.
[27] K. Weiss,et al. Spirometry use in clinical practice following diagnosis of COPD. , 2006, Chest.
[28] D. Price,et al. Scoring system and clinical application of COPD diagnostic questionnaires. , 2006, Chest.
[29] D. Mannino,et al. Lung function decline and outcomes in an elderly population , 2005, Thorax.
[30] C. Irvin,et al. Knowledge and use of office spirometry for the detection of chronic obstructive pulmonary disease by primary care physicians. , 2005, Respiratory care.
[31] D. Price,et al. Questions for COPD diagnostic screening in a primary care setting. , 2005, Respiratory medicine.
[32] A. Lindberg,et al. Prevalence of Chronic Obstructive Pulmonary Disease according to BTS, ERS, GOLD and ATS Criteria in Relation to Doctor’s Diagnosis, Symptoms, Age, Gender, and Smoking Habits , 2005, Respiration.
[33] A. Gulsvik,et al. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study , 2005, Thorax.
[34] R. Nordyke,et al. Comparison of existing symptom‐based questionnaires for identifying COPD in the general practice setting , 2005, Respirology.
[35] A. Ionescu,et al. Attaining a correct diagnosis of COPD in general practice. , 2005, Respiratory medicine.
[36] I. Adcock,et al. Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy. , 2005, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.
[37] P. Calverley,et al. Development of a Population-Based Screening Questionnaire for COPD , 2005, COPD.
[38] T. Wilt,et al. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). , 2005, Evidence report/technology assessment.
[39] E. Bleecker,et al. Similarities and differences in asthma and COPD. The Dutch hypothesis. , 2004, Chest.
[40] W. MacNee,et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.
[41] D. Halpin. A further step in the process of developing better service and standards of care for patients with COPD , 2004 .
[42] E. Bleecker,et al. Changing patterns in asbestos-induced lung disease. , 2004, Chest.
[43] J. Wedzicha,et al. Validation of a chronic obstructive pulmonary disease screening questionnaire for population surveys. , 2004, Respiratory medicine.
[44] S. Spencer,et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.
[45] M. Decramer,et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey , 2002, European Respiratory Journal.
[46] T. Seemungal,et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.
[47] D. Mannino,et al. Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. , 2002, Morbidity and mortality weekly report. Surveillance summaries.
[48] J. Vestbo,et al. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? , 2002, American journal of respiratory and critical care medicine.
[49] D. Mannino,et al. Surveillance for asthma--United States, 1980-1999. , 2002, Morbidity and mortality weekly report. Surveillance summaries.
[50] A. Buist,et al. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. , 2000, Chest.
[51] M. Rudolf. The reality of drug use in COPD: the European perspective. , 2000, Chest.
[52] S. Yancey,et al. Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.
[53] J Vestbo,et al. A 15-year follow-up study of ventilatory function in adults with asthma. , 1998, The New England journal of medicine.
[54] Jones Js,et al. Life in the 21st century - a vision for all. , 1998 .
[55] T. Seemungal,et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[56] C. van Weel,et al. How to avoid underdiagnosed asthma/chronic obstructive pulmonary disease? , 1998, The Journal of asthma : official journal of the Association for the Care of Asthma.
[57] J. Connett,et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. , 1996, American journal of respiratory and critical care medicine.
[58] John L. Hankinson,et al. Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.
[59] A. Buist,et al. Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Baseline characteristics of randomized participants. , 1993, Chest.
[60] R M Gardner,et al. Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.
[61] R. Peto,et al. The natural history of chronic airflow obstruction. , 1977, British medical journal.